Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NRXP News: HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition
$25 million investment in HOPE to consist of Series A (non-dilutive to NRx shareholders) convertible into 1/3 of fully diluted HOPE equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions
Initial funding of $2.0 million for purchase of NRx common stock anticipated to close on or before January 29, with the first tranche of $6.75 million of $25.0 million investment to be invested in HOPE Therapeutics, Inc. on or before February 7, 2025, and the balance of $18.25 million by April 1, 2025
Funds will be used in conjunction with anticipated bank financing to initiate nationwide rollup strategy of interventional psychiatry clinics, starting with Kadima Neuropsychiatry (La Jolla, CA)
HOPE intends to initiate nationwide acquisition program in partnership with leading investment bank on or around February 1, 2025.
MIAMI, Jan. 28, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today announced the signing and of a Stock Purchase Agreement ("SPA") with Smith & Sauer, LLC, as the first step in a $27.0 million financing to fund the planned acquisition of HOPE clinics. The agreement signed today provides for the immediate funding of $2.0 million in NRx common stock and commits Smith and Sauer to purchase an additional $25 million in newly issued Series A Preferred Stock of HOPE, the proceeds of which are intended to be used to initiate a nationwide rollup of Interventional Psychiatry Clinics to treat patients with severe, suicidal depression and PTSD. The first $6.75 million tranche is committed by February 7, 2025, with the full $25 million committed on or before April 1, 2025.
The Company anticipates leveraging the Smith and Sauer investment with bank debt and similar instruments to fund an initial rollup of Interventional Psychiatry Clinics with anticipated revenues of approximately $100 million on a pro-forma basis by the end of 2025. Unlike "ketamine clinics" that are frequently operated by non-mental health professionals, HOPE anticipates building a best-in-class nationwide chain of facilities that combine treatment with ketamine and other psychedelic medications with Transcranial Magnetic Stimulation (TMS) and recently FDA-approved Digital Therapeutics to best serve patients with life-threatening depression, PTSD, and related disorders.
"Today's transaction caps several months of intensive work as we have identified best-in-class interventional psychiatry clinics and assembled the capital from both Anson Funds and Smith and Sauer to consummate the initial acquisitions. The resources committed today are anticipated to bring the Company to the $100 million revenue threshold. We have initiated a financial advisory relationship with a leading investment bank to assemble the next $400 million of capital required to build a national and international presence," said Jonathan Javitt, MD MPH Chairman of NRx Pharmaceuticals. "Psychedelic Medications such as ketamine, neuromodulation technologies such as TMS, and digital therapeutics have sparked a revolution in psychiatry where for the first time patients with life threatening conditions such as depression and PTSD hope for a brighter future. As we develop HOPE Therapeutics, we aim to bring that future to the 16 million Americans who consider ending their lives each year and the 45 million Americans who suffer from depression and PTSD."
"We are honored to partner with NRx and HOPE to tackle the pressing mental health challenges facing our nation, particularly within the military and veteran communities," said Dallas Sauer, Co-Founder of Smith & Sauer.
"This partnership underscores the critical importance of addressing mental health with innovative and accessible solutions," said Anita Nunes, Co-Founder of Smith & Sauer. "We are proud to support HOPE and NRx in their mission to bring transformative care to underserved communities, including our veterans and military families."
Readers are advised to consult the Current Report on Form 8-K that NRx intends to file with the Securities and Exchange Commission on or before January 31, 2025 for a complete description of the Stock Purchase Agreement Although no assurances can be given, closing of the additional $25 million investment in HOPE's Series A Preferred Stock remains subject to execution of definitive agreements and the satisfaction of standard closing conditions.
The information in this press release is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
About Smith & Sauer
Founded by Dallas Sauer and Anita Nunes, Smith & Sauer, LLC is a private investment firm specializing in strategic partnerships and capital investments across healthcare, technology, and emerging industries. With decades of experience in operational leadership, financial structuring, and technological innovation, Smith & Sauer is committed to fostering growth in mission-driven organizations. The firm's investment philosophy centers on long-term value creation, aligning financial performance with societal impact. By leveraging its expertise in health information technology and clinic integration, Smith & Sauer plays a pivotal role in advancing cutting-edge solutions to address critical healthcare challenges.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including the risk that the transactions contemplated by the LOI are not consummated, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, HOPE Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off HOPE Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL05942&sd=2025-01-28 View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-execute-agreement-for-27-million-funding-transaction-for-hope-clinic-acquisition-302361736.html
SOURCE NRx Pharmaceuticals, Inc.
$IVDN: Innovative Designs Inc. Reports Record Sales Results to Shareholders
PITTSBURGH, Pa - (NewMediaWire) - December 30, 2024 - Innovative Designs, Inc. (OTC Pink: IVDN) today issues the following letter to shareholders from new CEO Joseph A. Riccelli. This letter covers the Company's fiscal third quarter financial results and forward-looking projections, as well as a discussion of significant events in 2024 and plans for the future.
Key points in this letter include:
2024 Fiscal Third Quarter Revenues More Than Doubled Same Period in 2023.
First Nine Months of Fiscal 2024 Delivered Over a 285% Increase Over 2023.
Accelerating Order Flow and Record Backlog in 2024 vs. No Backlog in 2023.
Increasing Production Capabilities to Meet Rising Demand.
Plans for Investor Conference Call / Shareholders Meeting in the company's 2nd Quarter.
Dear IVDN Shareholders:
As the 2024 calendar year comes to a close, I would like to thank all those who have maintained an investment position and followed the developing Innovative Designs story for the marketing of our unmatched Evacuated (Vacuum) Cell R-6 Insultex House Wrap®. As reported in our latest financial filing, the Company's sales revenues for the fiscal third quarter ending July 31, 2024, reached over $250K, surpassing double the $124K total from the same period in 2023. For the trailing nine months from fiscal Q3 in 2024, revenues reached more than $640K, over a 280% increase over the $223K revenue results in 2023.
The Company's full fiscal year ended on October 31, 2024 and we are currently working to complete this financial report which will present even more rapid sales growth. We can now project a 2024 fiscal year-end total of over $1.2M. After this year-end report is filed, we will hold an investor conference call and shareholder's meeting in the second quarter. Sales growth is also continuing in our fiscal first quarter with the largest backorder for Insultex House Wrap® that the company has ever seen, by far vs. no backlog last year.
A significant catalyst to the surging sales of Insultex House Wrap® has been new government building codes calling for continuous insulation and exterior R-Value requirements which are going into effect across the USA. Insultex House Wrap® has proven to be the best overall solution to these new requirements in terms of performance, cost effectiveness and ease of installation. Insultex House Wrap® delivers all this thanks to its unique and patented vacuum cell structure design. No other product on the market today offers a vacuum cell structure. A vacuum is the best thermal insulation possible and only Insultex® incorporates countless evacuated cells. Insultex® also provides a moisture barrier and other key benefits that make it the best choice for home builders and home remodelers for jobs of any size.
Once a new customer buys Insultex House Wrap®, which is a disruptive technology in the building industry, we are finding that they continue to reorder. Insultex House Wrap® provides a substantial savings for new construction, adding an R-6 moisture barrier membrane that does not need additional insulation boards or other support as competitive products.
With the increasing demand for Insultex House Wrap®, one of our top priorities has become increasing new production to maintain a timely order flow. To this end, we have developed new production resources in the last few months which are now able to deliver higher levels of inventory for customers placing rising orders. As demand grows, we have plans for further manufacturing and production. New marketing programs and additional product certifications are also planned.
Lastly, I would like to address the corporate changes that have taken place at Innovative Designs in the last few months including the installation of myself as the new CEO, a position which I am committed to fully with high expectations. The Board of Directors has asked me to convey their sincere appreciation of my father, former CEO Joesph Riccelli, Sr. He has given the Company over 20 years of dedicated service and strong support, all while overseeing important accomplishments. Prior to stepping down as CEO earlier this year for health and family reasons, Joseph Riccelli, Sr. kept Innovative Designs functioning and developing despite many hardships. He also worked to preserve shareholder value by maintaining a small and manageable share structure which today still totals less than 40 million shares outstanding.
Going forward, we intend to keep our customers and shareholders regularly informed of our progress as we address the vital energy saving needs of the multi-billion dollar homebuilding industry. One of our top priorities will be timely filing on all of our future financial reports. We will also be exploring other marketing opportunities for our unique Insultex® material beyond the building industry. For any shareholders or home building/remodeling professionals who wish to speak to me directly I will be available by phone and email at the contact information below. My family and I, as well as everyone on the Innovative Designs team, wish you all a prosperous 2025 ahead.
Sincerely,
Joseph A. Riccelli, CEO
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit: http://www.insultexhousewrap.com and http://www.idigear.com
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph A. Riccelli, CEO
412-799-0350
riccellijjr@insultexhousewrap.com
http://www.insultexhousewrap.com
The Secrets of Graphite Deposits - $TORVF:
Most graphite deposits are not the same. Most were not formed under intense heat for hundreds of years.
Volt Carbon ($TORVF) has tested graphite from Sri Lanka, Madagascar, Africa and other parts of Quebec. The flake graphite is very different. Much has to be chemically purified to get battery grade anode material.
However, the graphite in northern Quebec, which was affected by an asteroid impact some 214 million years ago, is very unique in the fact that it all occurs close to surface and has very pure flakes. EPR has 12,025 hectares in their tenure and GEM has 11,000 hectares in theirs.
That is 86.3 square miles which has been chosen by its geophysics to possibly contain 100 million tonnes of ore averaging 17% contained graphite.
The Manitouwadge Area has 20-30% graphite.......Most graphite deposits run 2 to 6% contained graphite.
$ZIVO This is at least a $50 stock people. At least.
Licensing coccidiosis with a major animal pharma ..... and now adding avian flu into the mix as a new vertical for the bioactives ...... ALL NON ANTIBIOTICS OPTIONS ....... is big ..... VERY big.
It has been a long time coming. The current market value of this stock is just over $70 million ...... only has roughly 3.5 million shares out presently. Add coccidiosis license. Add avian flu treatment options to support animal immune health and reduce the spread. Not to mention there are a host of additional animal heath verticals in coccidiosis, bovine mastitis, and joint health ... and we aren't even talking human health options.
Make no mistake, this is at the very least a $1 Billion compony in due time. Coccidiosis in broiler chickens is just the start. Could ZIVO land emergency grant funding and emergency fast tracking for avian flu research and dev ? University of Delaware sez statistically significant results !!!
$ILLR AI-Powered Engagement! Triller Insights highlights the platform’s groundbreaking AI-driven transformation. ✨
https://www.youtube.com/watch?v=trYbvzzlWSc
$ACGX: Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023
No New Free Trading Shares have been issued for over 8 months
CHICAGO, Nov. 14, 2024 /PRNewswire/ -- Alliance Creative Group, Inc., (http://www.ACGX.us) (Stock Symbol OTC: ACGX) is pleased to announce the results of Operations for the Quarter Ending September 30, 2024.
Revenues for the Quarter ending September 30, 2024 ("Q3 2024") were $102,990 Gross Profits for the Quarter ending September 30, 2024 ("Q3 2024") were $102,990 Net Income for the Quarter ending September 30, 2024 ("Q3 2024") were ($44,912)
The total assets on the Balance Sheet for the Alliance Creative Group as of 9/30/24 were $4,543,643
The total outstanding common shares as of September 30, 2024 were 4,454,211 with 2,799,023 of those shares in the float - Same as the end of the last quarter, and since March.
The Company ended the quarter with $88,220 Cash on hand.
The property located at 1324 W. Devon Ave, Chicago, IL. 60660 has lowered its asking pricing and hopes to sell before the end of the year.
The full financial statement, balance sheet, statement of operations, cash flow statement, and disclosure statements are posted on the OTC Market Company website at http://www.OTCmarkets.com under the stock symbol ACGX in the section for filings and disclosure and on http://www.ACGX,us in the investor relations section.
Paul Sorkin, CEO of the Alliance Creative Group, Inc. said, "We continue to look for future opportunities, however, nothing has been a good fit yet. Our goal is to reduce the price significantly with the 1324 W. Devon Ave property so we can sell it before the end of the year and increase our search for the next opportunity. Our shares of www.PeopleVine.com continue to be by far our strongest investment and the conversations with the growth capital investment groups have been avery positive experience with lots of interest. Our goal is to convert between 20% and 30% of the PeopleVine investment into cash in 2025 so we can use a lot of it to invest in future projects while we let the majority of the shares hopefully continue to increase in value.
We haven't issued any new free trading shares in over 8 months now and we are still in search of other strategic investments, acquisitions, or partnerships in Real Estate or in a small business with good potential to grow. We will continue to update the public as things progress and will share more details as they become available."
About Alliance Creative Group, Inc.
Alliance Creative Group, Inc. (Stock Symbol: ACGX) is a Parent Holding Company on the OTC market. The strategy ACG intends to deploy is a shared resource model where internal divisions, portfolio companies, Real Estate projects, and strategic investments are vertically integrated, optimizing efficiencies and cost savings. Resources may be applied to a mix of early-stage equity investments in companies that synergize with the company's shared resource model and secured investment opportunities. ACG's strategic mission is to utilize a unique blend of capital, relationships, experience, and secured investment structures to increase value for its clients, partners, investors, and shareholders while reducing the overall risk. The company's big picture long term plan is to create an ecosystem of shared resources that can provide quality resources with reduced expenses while acting as a partner for internal projects. The intent is to have multiple businesses and investment projects or divisions to help diversify the risk and generate potential revenue in multiple ways while leveraging both the private and public markets. For more information, visit http://www.AllianceCreativeGroup.com or http://www.ACGX.us.
About PeopleVine
PeopleVine is a Software as a Service (SAAS) company that specializes in serving the Lifestyle Hospitality industry. The Member Experience & CRM Software allows luxury hotels, resorts, and private member clubs to elevate a more personalized online membership experience. PeopleVine helps their clients build member communities, drive engagement, and connect the dots that elevate experiences and revenues. The software empowers its clients teams to deliver efficiently managed operations through an integrated platform. PeopleVine is committed to being the most essential and adaptive SaaS engagement platform for companies that take a customer centric approach to business.
For more information http://www.PeopleVine.com
This news release contains forward-looking statements as defined by the bespeaks-caution doctrine. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Investor Relations and Media Contact
1-312-498-9769, info@ACGemail.com
Cision View original content:https://www.prnewswire.com/news-releases/alliance-creative-group-acgx-releases-q3-2024-financial-and-disclosure-report-with-an-increase-of-over-100-in-net-income-for-1st-9-months-of-2024-vs-2023-302304712.html
SOURCE Alliance Creative Group, Inc.
$BLIS News: NAPC Defense (OTCPK: BLIS) issues new Progress Report regarding Large Contract with Saudi Arabia, Live-Fire Demos for U.S. based Police and SWAT, Manufacturing update, and more
LARGO, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NAPC Defense, Inc., (OTCPK: BLIS) (“NAPC” or “the Company”) announces that the Company is making strong progress on its CornerShot USA weapons systems and other initiatives.
NAPC’s Management believes the Company is well positioned to drive significant revenue and profits in 2025, from its own manufacturing and sale of CornerShot in the United States and Saudi Arabia. NAPC maintains it will also drive revenue through the brokering of arms and munitions, as well as contract work for renovation and clean up, following recent hurricanes in the area.
As previously announced, NAPC received a signed and stamped Letter of Intent from Saudi Arabia for an initial order of 37,000 CornerShot units, valued at (U.S.) $370 million. Management has already conducted critical late-stage meetings and live-fire demonstrations in Saudi Arabia with several military divisions through visits to the country in August and October of 2024.
NAPC Defense has now received a request to complete live fire demonstrations in Saudi Arabia from Saudi Land Forces. The visit is planned to take place between December 29, 2024 and January 12, 2025. The Company previously reported that this upcoming visit would take place last month.
Please see below for a list of current and anticipated NAPC developments, as we enter the New Year:
Following the next phase of the upcoming CornerShot demonstrations in Saudi Arabia, NAPC expects that it will enter final contract negotiations, deposit funding, and initial CornerShot manufacturing. in Q1 of 2025.
NAPC has secured manufacturing facilities for the production of CornerShot USA weapons systems in Pinellas Park, FL. The space is large enough to meet anticipated demand for the near future.
Live-fire demonstrations were recently conducted for St. Petersburg Police and SWAT teams in Pinellas County. New orders from these departments, as well as others, are expected in January 2025.
NAPC Defense has secured booth space #10953 at the upcoming SHOT Show in Las Vegas from January 21-24, 2025. The SHOT Show is the largest and most comprehensive trade show for all professionals involved with the shooting sports, hunting and law enforcement industries.
In addition to over $1.5 million in new hurricane renovation and cleanup work in Pinellas Country, the Company has partnered with another firm in an effort to win an additional $3 million in contracts.
CEO Kenny West stated, “This is truly an exciting time for NAPC Defense. We have laid the groundwork in 2024, and now it’s time to deliver in 2025. We appreciate the ongoing support from our shareholders and investors.”
About NAPC Defense, Inc.
NAPC Defense, Inc. https://www.napcdefense.com/ is an armament sales and production company, fully licensed in the United States, with exclusive rights to produce and sell CornerShot USA weapons systems in the U.S and Saudi Arabia, in addition to brokering arms and munitions throughout the world all with US State Department approval. Additional smaller weapons platforms, a series of ballistics protection technologies and related products are in development or being finalized for sale.
FORWARD LOOKING STATEMENTS:
This press release and the statements of representatives of NAPC (the "Company") related thereto contain, or may contain, among other things, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are "forward-looking statements," including any other statements of non-historical information.
These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as "guidance," "projects," "may," "could," "would," "should,’ “believes," "expects," "anticipates,” “estimates," "intends," "plans, “ultimately" or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results (including, without limitation, NAPC's ability to advance its business, generate revenue and profit and operate as a public company) could differ materially from those stated or anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.
COMPANY CONTACT:
Kenny West, CEO (754) 242-6272 Ext.713
https://www.globenewswire.com/newsroom/ti?nf=OTMxODA3MiM2NjM0MDk5IzIyNjE1MDY=
https://ml.globenewswire.com/media/ZTE0MTNkZDEtNzcyMi00YmU0LTk2YTEtMThmMDA4NDI4NGEwLTEyNzMwNTY=/tiny/NAPC-Defense-Inc-.png
Source: NAPC Defense, Inc.
$HNOI News: HNO International and Pneumatic and Hydraulic Company Sign Teaming Agreement to Advance Scalable Hydrogen Energy Solutions
HOUSTON, Dec. 5, 2024 /PRNewswire/ -- HNO International, Inc. (OTC: HNOI) and Pneumatic and Hydraulic Company (PHC) have signed a formal teaming agreement to accelerate the deployment of scalable hydrogen energy systems. This collaboration will leverage PHC's expertise in fluid power systems, power distribution, and service capabilities to support HNO International's vision of deploying hundreds of 1-10 megawatt electrolyzer production plants, refuelers (mobile and stationary), hydrogen refueling systems, and microgrid solutions.
PHC, a leader in the compressed gas industry for over 60 years, is the largest North American distributor for Haskel and serves a broad range of industries, including notable aerospace clients like SpaceX, Blue Origin, and NASA. Their affiliate company also provides power distribution technology to the majority of major datacenters in the United States, supporting clients such as Amazon, Meta, and Microsoft. Their extensive experience in fluid power solutions and high-pressure systems, along with their distribution lines of over 55 American-made brands of related equipment, will be instrumental in this partnership. PHC's robust service and repair infrastructure ensures long-term operational reliability, a critical factor in deploying cutting-edge hydrogen systems.
HNOI, with more than 15 years at the forefront of green hydrogen-based clean energy technologies, has a proven track record in delivering scalable, innovative hydrogen solutions. Their Scalable Hydrogen Energy Platform (SHEP™) and Compact Hydrogen Refueling System (CHRS™) are designed to provide modular and rapidly deployable hydrogen production and dispensing solutions that meet the growing demand for clean energy across transportation, industrial, and energy sectors.
"This teaming agreement solidifies a partnership that combines HNO's innovative hydrogen solutions with PHC's exceptional integration, distribution, and service expertise," said Don Owens, Chairman of HNO International. "Together, we are taking a significant step forward in advancing the hydrogen economy and delivering clean energy solutions at scale."
The partnership emphasizes a shared commitment to transforming energy systems through efficient, reliable, and scalable hydrogen technologies. By pooling their resources and expertise, HNO International and PHC are positioned to address the challenges of clean energy adoption and drive the hydrogen economy forward.
About HNO International, Inc
HNO International (HNOI) is a company specializing in the design, integration, and development of green hydrogen-based energy technologies. With over 15 years of experience in green hydrogen production, HNOI and its leadership team are on a mission to help lead the renewable energy transition by making energy accessible to businesses and communities worldwide. Their pioneering solutions, including the Scalable Hydrogen Energy Platform (SHEP™) and the Compact Hydrogen Refueling Station (CHRS™), are setting new standards for green hydrogen production.
About Pneumatic and Hydraulic Company
PHC, a leader in the compressed gas industry for over 60 years, is the largest North American distributor for Haskel and serves a broad range of industries, including notable aerospace clients like SpaceX, Blue Origin, and NASA. Their extensive experience in fluid power solutions, high-pressure systems, and power distribution makes them a trusted partner in energy infrastructure.
Forward-Looking Statements
This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.
https://c212.net/c/img/favicon.png?sn=LA72869&sd=2024-12-05 View original content to download multimedia:https://www.prnewswire.com/news-releases/hno-international-and-pneumatic-and-hydraulic-company-sign-teaming-agreement-to-advance-scalable-hydrogen-energy-solutions-302323766.html
SOURCE HNO International
$ILLR ✨Triller is Building a Digital Economy Powerhouse:
$4 Billion Merger Now Complete. Triller aims to accelerate innovation, drive rapid growth, and expand their market presence globally🌐
$ILLR With over 430M+ consumer accounts and a reach of 100M+ social media users, Triller Group is redefining how content is created and shared. Our platform integrates AI and machine learning to deliver unparalleled experiences. #TrillerGroup #DigitalTransformation
https://x.com/triller_IR/status/1849805614387691849